Arcutis Biotherapeutics logo

Arcutis BiotherapeuticsNASDAQ: ARQT

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

31 January 2020

Next earnings report:

27 February 2025

Last dividends:

N/A

Next dividends:

N/A
$1.17 B
-28%vs. 3y high
75%vs. sector
-vs. 3y high
-vs. sector
-48%vs. 3y high
89%vs. sector
-99%vs. 3y high
75%vs. sector

Price

regular market | 3 min ago
$9.97+$0.13(+1.32%)

Dividend

No data over the past 3 years
$44.76 M$54.67 M
$44.76 M-$41.54 M

Analysts recommendations

Institutional Ownership

ARQT Latest News

Arcutis Biotherapeutics, Inc. (ARQT) Crossed Above the 50-Day Moving Average: What That Means for Investors
zacks.com20 November 2024 Sentiment: -

After reaching an important support level, Arcutis Biotherapeutics, Inc. (ARQT) could be a good stock pick from a technical perspective. ARQT surpassed resistance at the 50-day moving average, suggesting a short-term bullish trend.

Arcutis Biotherapeutics, Inc. (ARQT) Recently Broke Out Above the 200-Day Moving Average
zacks.com20 November 2024 Sentiment: -

From a technical perspective, Arcutis Biotherapeutics, Inc. (ARQT) is looking like an interesting pick, as it just reached a key level of support. ARQT recently overtook the 200-day moving average, and this suggests a long-term bullish trend.

Arcutis Biotherapeutics: +200% On ZORYVE Approval, But When Is The Next Leg Up?
seekingalpha.com15 November 2024 Sentiment: POSITIVE

Following the successful product launch of Zoryve, Arcutis Biotherapeutics has returned an impressive +200% year-to-date. Recent Q3 earnings impressed, with a blistering 452% year-over-year and 45% quarter-over-quarter revenue growth. The growth trend seems poised to continue, with an expanding total patient opportunity and the industry trending away from topical steroids, which present lower efficacy and higher risk.

Wall Street Analysts See a 70.33% Upside in Arcutis Biotherapeutics (ARQT): Can the Stock Really Move This High?
zacks.com11 November 2024 Sentiment: POSITIVE

The consensus price target hints at a 70.3% upside potential for Arcutis Biotherapeutics (ARQT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Arcutis Biotherapeutics, Inc. (ARQT) Q3 2024 Earnings Call Transcript
seekingalpha.com07 November 2024 Sentiment: NEUTRAL

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT ) Q3 2024 Earnings Conference Call November 6, 2024 4:30 PM ET Company Participants Latha Vairavan - Vice President, Finance and Investor Relations Frank Watanabe - President and CEO Todd Edwards - Chief Commercial Officer Patrick Burnett - Chief Medical Officer David Topper - Chief Financial Officer Conference Call Participants Vikram Purohit - Morgan Stanley Seamus Fernandez - Guggenheim Securities Uy Ear - Mizuho Serge Belanger - Needham & Co. Kambiz Yazdi - Jefferies Operator Good day, and welcome to the Arcutis Biotherapeutics 2024 Third Quarter Financial Results Conference Call. At this time, all participants are in a listen-only mode.

Arcutis Biotherapeutics, Inc. (ARQT) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
zacks.com25 October 2024 Sentiment: NEGATIVE

Arcutis Biotherapeutics (ARQT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Arcutis Announces Health Canada Approval of ZORYVE® (Roflumilast) Foam 0.3% to Treat Seborrheic Dermatitis in Individuals 9 Years of Age and Older
globenewswire.com18 October 2024 Sentiment: POSITIVE

ZORYVE foam represents the first topical treatment for seborrheic dermatitis with a new mechanism of action approved in Canada in over two decades1 Second approval of ZORYVE outside of the United States, expanding ZORYVE portfolio availability to over 2 million Canadians living with seborrheic dermatitis WESTLAKE VILLAGE, Calif., Oct. 18, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc.  (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that its wholly-owned subsidiary Arcutis Canada, Inc. has received regulatory approval from Health Canada for ZORYVE (roflumilast) topical foam 0.3% for the treatment of seborrheic dermatitis in patients 9 years of age and older.

New Data Shows ZORYVE® (Roflumilast) Cream 0.15% Provided Consistent Improvement of Atopic Dermatitis in Individuals With Diverse Skin Types
globenewswire.com25 September 2024 Sentiment: POSITIVE

ZORYVE demonstrated consistent efficacy in disease clearance and reduction in itch for individuals with atopic dermatitis (AD) regardless of race, ethnicity, and Fitzpatrick skin type ZORYVE was safe and well tolerated across all subgroups Data presented at the 2024 European Academy of Dermatology & Venereology Congress WESTLAKE VILLAGE, Calif., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc.  (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology and immunology, today announced new pooled subgroup analysis results from the Phase 3 INTEGUMENT-1 and -2 trials showing that ZORYVE cream 0.15% provided consistent and meaningful improvements in signs and symptoms of AD in individuals regardless of race, ethnicity, and Fitzpatrick skin types.

FDA Accepts Arcutis' Supplemental New Drug Application for ZORYVE® (roflumilast) Foam for the Treatment of Scalp and Body Psoriasis in Adults and Adolescents Ages 12 and Over
globenewswire.com24 September 2024 Sentiment: POSITIVE

U.S. Food and Drug Administration (FDA) has set a Prescription Drug User Fee Act (PDUFA) target action date of May 22, 2025 Almost half of the 9 million individuals in the United States with plaque psoriasis experience involvement of the scalp Supplemental New Drug Application (sNDA) supported by positive efficacy and safety data from Phase 2b and pivotal Phase 3 trials, and long-term ZORYVE cream plaque psoriasis program WESTLAKE VILLAGE, Calif., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc.  (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced the FDA has accepted its sNDA for ZORYVE (roflumilast) foam 0.3%, a once-daily, next generation phosphodiesterase-4 (PDE4) inhibitor, for the treatment of adults and adolescents ages 12 and over with scalp and body psoriasis.

Arcutis: Shares Plateau After Early 2024 Gains, But Further Upside Looks Likely
seekingalpha.com22 August 2024 Sentiment: POSITIVE

Arcutis Biotherapeutics, Inc. is a biotech company based in California that markets two dermatological products, ZORYVE cream and foam, containing roflumilast, a PDE4 inhibitor. Despite initial struggles post-IPO, Arcutis has seen a significant increase in revenues and a narrowing of losses in Q2 2024, with new product approvals and collaborations. Analysts predict strong growth potential for ZORYVE, but competition in the dermatological market poses a challenge for Arcutis to maintain and grow market share.

  • 1(current)
  • 2
  • 3

What type of business is Arcutis Biotherapeutics?

Arcutis Biotherapeutics, Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for dermatological diseases. The company was previously known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Our company is headquartered in Westlake Village, California. The company has a broad portfolio of drugs with significant potential for treating immune-mediated dermatological diseases and conditions. The company's lead product candidate is ARQ-151, a cream with roflumilast for the treatment of plaque psoriasis. The company is also developing ARQ-154, a roflumilast foam formulation for topical use to treat seborrheic dermatitis and scalp psoriasis. ARQ-252, a selective topical Janus kinase type 1 inhibitor for the treatment of chronic hand eczema and vitiligo. ARQ-255, a local formulation of ARQ-252, developed for deeper penetration into the skin to treat focal alopecia.

What sector is Arcutis Biotherapeutics in?

Arcutis Biotherapeutics is in the Healthcare sector

What industry is Arcutis Biotherapeutics in?

Arcutis Biotherapeutics is in the Biotechnology industry

What country is Arcutis Biotherapeutics from?

Arcutis Biotherapeutics is headquartered in United States

When did Arcutis Biotherapeutics go public?

Arcutis Biotherapeutics initial public offering (IPO) was on 31 January 2020

What is Arcutis Biotherapeutics website?

https://www.arcutis.com

Is Arcutis Biotherapeutics in the S&P 500?

No, Arcutis Biotherapeutics is not included in the S&P 500 index

Is Arcutis Biotherapeutics in the NASDAQ 100?

No, Arcutis Biotherapeutics is not included in the NASDAQ 100 index

Is Arcutis Biotherapeutics in the Dow Jones?

No, Arcutis Biotherapeutics is not included in the Dow Jones index

When was Arcutis Biotherapeutics the previous earnings report?

No data

When does Arcutis Biotherapeutics earnings report?

The next expected earnings date for Arcutis Biotherapeutics is 27 February 2025